• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用伪双功能聚乙二醇-十六烷进行N端修饰显著改善人生长激素的药理学特性。

N-Terminal Modification with Pseudo-Bifunctional PEG-Hexadecane Markedly Improves the Pharmacological Profile of Human Growth Hormone.

作者信息

Wu Ling, Ji Shaoyang, Hu Tao

机构信息

†National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.

‡University of Chinese Academy of Sciences, Beijing 100190, China.

出版信息

Mol Pharm. 2015 May 4;12(5):1402-11. doi: 10.1021/mp500680p. Epub 2015 Apr 20.

DOI:10.1021/mp500680p
PMID:25849255
Abstract

Human growth hormone (hGH) has been used to treat children with short stature, renal failure, and Turner's syndrome. However, clinical application of hGH suffers from its short plasma half-life and low bioavailability. PEGylation and albumin binding are two of the most effective approaches to prolong the plasma half-life of hGH. However, the steric shielding effects of polyethylene glycol (PEG) and albumin can drastically decrease the bioactivity of hGH, which is opposite to the increased pharmacokinetics (PK). In the present study, a long-acting hGH with markedly improved pharmacological profile was rationally designed and prepared by N-terminal modification of hGH with pseudo-bifunctional PEG-hexadecane by using PEG (3.5 kDa or 10 kDa) as the linker. PEGylation and albumin binding with hexadecane can increase the hydrodynamic volume and decrease the immunogenicity of hGH, which thereby markedly increases the PK of hGH. Since N-terminus is far from the bioactive domain of hGH, N-terminal modification of hGH can minimize the steric shielding effects on the bioactive domain of hGH. Hexadecane-bound albumin can be slowly released from hGH during the in vivo circulation, which can slowly restore the bioactivity of hGH. Thus, the high bioactivity of PEG-hexadecane modified hGH (hGH-PEG-HD) was synergistically achieved by N-terminal modification with pseudo-bifunctional PEG-hexadecane and slow-release of albumin. The high pharmacodynamics (PD) of hGH-PEG-HD was due to the synergistic effect of the high bioactivity and the overall increased PK.

摘要

人生长激素(hGH)已被用于治疗身材矮小、肾衰竭和特纳综合征的儿童。然而,hGH的临床应用受到其血浆半衰期短和生物利用度低的困扰。聚乙二醇化和白蛋白结合是延长hGH血浆半衰期最有效的两种方法。然而,聚乙二醇(PEG)和白蛋白的空间屏蔽效应会大幅降低hGH的生物活性,这与药代动力学(PK)的增加相反。在本研究中,通过使用PEG(3.5 kDa或10 kDa)作为连接体,用假双功能PEG-十六烷对hGH进行N端修饰,合理设计并制备了一种药理特性显著改善的长效hGH。PEG化和与十六烷结合的白蛋白可以增加流体动力学体积并降低hGH的免疫原性,从而显著提高hGH的PK。由于N端远离hGH的生物活性结构域,对hGH进行N端修饰可以最大限度地减少对hGH生物活性结构域的空间屏蔽效应。与十六烷结合的白蛋白在体内循环过程中可以从hGH中缓慢释放,从而可以缓慢恢复hGH的生物活性。因此,通过用假双功能PEG-十六烷进行N端修饰和白蛋白的缓慢释放,协同实现了PEG-十六烷修饰的hGH(hGH-PEG-HD)的高生物活性。hGH-PEG-HD的高药效学(PD)归因于高生物活性和整体增加的PK的协同作用。

相似文献

1
N-Terminal Modification with Pseudo-Bifunctional PEG-Hexadecane Markedly Improves the Pharmacological Profile of Human Growth Hormone.用伪双功能聚乙二醇-十六烷进行N端修饰显著改善人生长激素的药理学特性。
Mol Pharm. 2015 May 4;12(5):1402-11. doi: 10.1021/mp500680p. Epub 2015 Apr 20.
2
Phenyl amide linker improves the pharmacokinetics and pharmacodynamics of N-terminally mono-PEGylated human growth hormone.苯基酰胺连接子改善了N端单聚乙二醇化人生长激素的药代动力学和药效学。
Mol Pharm. 2014 Sep 2;11(9):3080-9. doi: 10.1021/mp500266c. Epub 2014 Aug 21.
3
Chemical and Enzymatic Site Specific PEGylation of hGH: The Stability and in vivo Activity of PEG-N-Terminal-hGH and PEG-Gln141-hGH Conjugates.人生长激素的化学及酶促位点特异性聚乙二醇化:聚乙二醇化N端人生长激素和聚乙二醇化谷氨酰胺141人生长激素缀合物的稳定性及体内活性
Macromol Biosci. 2016 Jan;16(1):50-6. doi: 10.1002/mabi.201500282. Epub 2015 Sep 9.
4
Chemical and enzymatic site specific PEGylation of hGH.人 GH 的化学和酶切位点特异性聚乙二醇化。
Bioconjug Chem. 2013 Mar 20;24(3):456-63. doi: 10.1021/bc300594y. Epub 2013 Mar 4.
5
N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.生长激素拮抗剂的 N 端单聚乙二醇化:PEG 大小与药效学行为的相关性。
Int J Pharm. 2013 Sep 10;453(2):533-40. doi: 10.1016/j.ijpharm.2013.06.022. Epub 2013 Jun 21.
6
Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone.精确的组合聚乙二醇化可生成低免疫原性和稳定的人生长激素形式。
J Control Release. 2017 Mar 10;249:84-93. doi: 10.1016/j.jconrel.2017.01.029. Epub 2017 Jan 25.
7
A new PEG-beta-alanine active derivative for releasable protein conjugation.一种用于可释放蛋白质偶联的新型聚乙二醇化β-丙氨酸活性衍生物。
Bioconjug Chem. 2008 Dec;19(12):2427-31. doi: 10.1021/bc800281s.
8
Pharmacokinetic/pharmacodynamic (PK/PD) differentiation of native and PEGylated recombinant human growth hormone (rhGH and PEG-rhGH) in the rat model of osteoarthritis.在骨关节炎大鼠模型中天然和聚乙二醇化重组人生长激素(rhGH和PEG-rhGH)的药代动力学/药效学(PK/PD)差异
Xenobiotica. 2010 Aug;40(8):586-92. doi: 10.3109/00498254.2010.488303.
9
Thiolated glycol chitosan bearing α-cyclodextrin for sustained delivery of PEGylated human growth hormone.负载α-环糊精的硫醇化乙二醇壳聚糖用于聚乙二醇化人生长激素的持续递送
J Biomater Sci Polym Ed. 2012;23(15):1995-2005. doi: 10.1163/092050611X603700. Epub 2012 May 8.
10
Troubleshooting PEG-hGH detection supporting pharmacokinetic evaluation in growth hormone deficient patients.解决聚乙二醇化重组人生长激素检测问题,以支持生长激素缺乏患者的药代动力学评估。
J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):92-7. doi: 10.1016/j.vascn.2009.12.004. Epub 2010 Jan 4.

引用本文的文献

1
Growth hormone receptor agonists and antagonists: From protein expression and purification to long-acting formulations.生长激素受体激动剂和拮抗剂:从蛋白表达和纯化到长效制剂。
Protein Sci. 2023 Sep;32(9):e4727. doi: 10.1002/pro.4727.
2
Preparation and Characterization of Site-Specific Fatty Chain-Modified Recombinant Human Granulocyte Colony Stimulating Factor.位点特异性脂肪酸链修饰的重组人粒细胞集落刺激因子的制备与表征
Front Bioeng Biotechnol. 2022 May 23;10:923059. doi: 10.3389/fbioe.2022.923059. eCollection 2022.